These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

125 related items for PubMed ID: 23190694

  • 1. Contrast-enhanced whole body joint MR imaging in rheumatoid patients on tumour necrosis factor-alpha agents: a pilot study to evaluate novel scoring system for MR synovitis.
    Kamishima T, Kato M, Atsumi T, Koike T, Onodera Y, Terae S.
    Clin Exp Rheumatol; 2013; 31(1):154. PubMed ID: 23190694
    [No Abstract] [Full Text] [Related]

  • 2. Delayed treatment with tumor necrosis factor inhibitors in incomplete responders to synthetic disease-modifying anti-rheumatic drugs shows an excellent effect in patients with very early rheumatoid arthritis with poor prognosis factors.
    Kita J, Tamai M, Arima K, Nakashima Y, Suzuki T, Kawashiri SY, Okada A, Koga T, Yamasaki S, Nakamura H, Origuchi T, Aramaki T, Nakashima M, Fujikawa K, Tsukada T, Ida H, Aoyagi K, Uetani M, Eguchi K, Kawakami A.
    Mod Rheumatol; 2012 Apr; 22(2):195-201. PubMed ID: 21898075
    [Abstract] [Full Text] [Related]

  • 3. Response of early active rheumatoid arthritis to tumor necrosis factor inhibitors: evaluation by magnetic resonance imaging.
    Hirose W, Nishikawa K, Hirose M, Nanki T, Sugimoto H.
    Mod Rheumatol; 2009 Apr; 19(1):20-6. PubMed ID: 18762862
    [Abstract] [Full Text] [Related]

  • 4. Predictive value of ultrasonographic assessment of disease activity in response to tumor necrosis factor-α inhibitor treatment in rheumatoid arthritis: a prospective cohort study.
    Inanc N, Ozen G, Direskeneli H.
    Clin Exp Rheumatol; 2016 Apr; 34(1):156. PubMed ID: 26575409
    [No Abstract] [Full Text] [Related]

  • 5. Etanercept reduces synovitis as measured by magnetic resonance imaging in patients with active rheumatoid arthritis after only 6 weeks.
    Lisbona MP, Maymo J, Perich J, Almirall M, Pérez-García C, Carbonell J.
    J Rheumatol; 2008 Mar; 35(3):394-7. PubMed ID: 18203329
    [Abstract] [Full Text] [Related]

  • 6. Lessons from magnetic resonance imaging studies in rheumatoid arthritis.
    Quinn M.
    J Rheumatol; 2008 Mar; 35(3):372-4. PubMed ID: 18322971
    [No Abstract] [Full Text] [Related]

  • 7. Etanercept maintains the clinical benefit achieved by infliximab in patients with rheumatoid arthritis who discontinued infliximab because of side effects.
    Iannone F, Trotta F, Montecucco C, Giacomelli R, Galeazzi M, Matucci-Cerinic M, Ferri C, Cutolo M, Maria Bambara L, Triolo G, Ferraccioli G, Valentini G, Lapadula G, GISEA (Gruppo Italiano per lo Studio delle Early Arthritis).
    Ann Rheum Dis; 2007 Feb; 66(2):249-52. PubMed ID: 16837489
    [Abstract] [Full Text] [Related]

  • 8. Tight control is important in patients with rheumatoid arthritis treated with an anti-tumor necrosis factor biological agent: prospective study of 91 cases who used a biological agent for more than 1 year.
    Sano H, Arai K, Murai T, Fujisawa J, Kondo N, Netsu T, Hanyu T, Saeki T, Ito T, Endo N.
    Mod Rheumatol; 2009 Feb; 19(4):390-4. PubMed ID: 19466615
    [Abstract] [Full Text] [Related]

  • 9. Anti-TNF scintigraphy to assess TNF-α-associated joint inflammation in rheumatoid arthritis and osteoarthritis.
    Hermann J, Lipp RW, Dunzinger A, Spreizer C, Schaffler G, Kvaternik H, Ofner P, Graninger W.
    Clin Exp Rheumatol; 2014 Feb; 32(4):614. PubMed ID: 24959905
    [No Abstract] [Full Text] [Related]

  • 10. A new low-field extremity magnetic resonance imaging and proposed compact MRI score: evaluation of anti-tumor necrosis factor biologics on rheumatoid arthritis.
    Suzuki T, Ito S, Handa S, Kose K, Okamoto Y, Minami M, Hayashi T, Goto D, Matsumoto I, Sumida T.
    Mod Rheumatol; 2009 Feb; 19(4):358-65. PubMed ID: 19370385
    [Abstract] [Full Text] [Related]

  • 11. [Anti-TNF alpha agents in patients with rheumatoid arthritis refractory to conventional therapies].
    González-Gay MA, Agudo M.
    Med Clin (Barc); 2010 May 22; 134(15):684-5. PubMed ID: 20176386
    [No Abstract] [Full Text] [Related]

  • 12. Power Doppler ultrasonographic monitoring of response to anti-tumor necrosis factor therapy in patients with rheumatoid arthritis.
    Naredo E, Möller I, Cruz A, Carmona L, Garrido J.
    Arthritis Rheum; 2008 Aug 22; 58(8):2248-56. PubMed ID: 18668537
    [Abstract] [Full Text] [Related]

  • 13. Etanercept and infliximab for rheumatoid arthritis.
    Drug Ther Bull; 2001 Jul 22; 39(7):49-52. PubMed ID: 11471515
    [Abstract] [Full Text] [Related]

  • 14. Treatment with tumour necrosis factor alpha antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies.
    Jonsdottir T, Forslid J, van Vollenhoven A, Harju A, Brannemark S, Klareskog L, van Vollenhoven RF.
    Ann Rheum Dis; 2004 Sep 22; 63(9):1075-8. PubMed ID: 15066863
    [Abstract] [Full Text] [Related]

  • 15. Persistence with anti-tumor necrosis factor therapies in patients with rheumatoid arthritis: observations from the RADIUS registry.
    Markenson JA, Gibofsky A, Palmer WR, Keystone EC, Schiff MH, Feng J, Baumgartner SW.
    J Rheumatol; 2011 Jul 22; 38(7):1273-81. PubMed ID: 21572150
    [Abstract] [Full Text] [Related]

  • 16. Golimumab in patients with active rheumatoid arthritis after treatment with tumour necrosis factor alpha inhibitors (GO-AFTER study): a multicentre, randomised, double-blind, placebo-controlled, phase III trial.
    Smolen JS, Kay J, Doyle MK, Landewé R, Matteson EL, Wollenhaupt J, Gaylis N, Murphy FT, Neal JS, Zhou Y, Visvanathan S, Hsia EC, Rahman MU, GO-AFTER study investigators.
    Lancet; 2009 Jul 18; 374(9685):210-21. PubMed ID: 19560810
    [Abstract] [Full Text] [Related]

  • 17. Which TNF inhibitor for rheumatoid arthritis?
    Med Lett Drugs Ther; 2010 May 17; 52(1338):38-9. PubMed ID: 20467356
    [No Abstract] [Full Text] [Related]

  • 18. May etanercept and PTH (1-34) association heal erosions in early rheumatoid arthritis? A pilot study.
    Migliore A, Massafra U, Bizzi E, Argento G, Diamanti AP, Germano V, Tormenta S, Arduini F, Iannessi F, Granatas M, Laganà B.
    Eur Rev Med Pharmacol Sci; 2012 Mar 17; 16(3):363-9. PubMed ID: 22530354
    [Abstract] [Full Text] [Related]

  • 19. Imaging progression despite clinical remission in early rheumatoid arthritis patients after etanercept interruption.
    Laganà B, Picchianti Diamanti A, Ferlito C, Germano V, Migliore A, Cremona A, Argento G, David V, Salemi S, D'Amelio R.
    Int J Immunopathol Pharmacol; 2009 Mar 17; 22(2):447-54. PubMed ID: 19505397
    [Abstract] [Full Text] [Related]

  • 20. Do the clinical responses and complications following etanercept or infliximab therapy predict similar outcomes with the other tumor necrosis factor-alpha antagonists in patients with rheumatoid arthritis?
    Ang HT, Helfgott S.
    J Rheumatol; 2003 Nov 17; 30(11):2315-8. PubMed ID: 14677170
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 7.